Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$131.49 USD

131.49
142,467

-0.94 (-0.71%)

Updated Oct 15, 2024 04:00 PM ET

After-Market: $131.54 +0.05 (0.04%) 7:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (82 out of 250)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Tirthankar Chakraborty headshot

New Strong Buy Stocks for February 26th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Integer Holdings' (ITGR) 2019 View Strong Despite Rivalry

Integer Holdings (ITGR) holds a solid position in the MedTech space but is still exposed to competition.

Integer Holdings' (ITGR) Q4 Earnings Beat, '19 View Strong

Integer Holdings (ITGR) gains from the core Medical Sales segment's impressive performance in fourth-quarter 2018.

Integer (ITGR) Surpasses Q4 Earnings and Revenue Estimates

Integer (ITGR) delivered earnings and revenue surprises of 13.04% and 1.74%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Integer (ITGR) Q4 Earnings Expected to Decline

Integer (ITGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Integer Holdings (ITGR) Stock Outpacing Its Medical Peers This Year?

Is (ITGR) Outperforming Other Medical Stocks This Year?

Here's Why Investors Should Hold Patterson Companies Stock

Patterson Companies (PDCO) gains from solid foothold in theAnimals Health business. However, the company is facing headwinds in the Dental segment.

Here's Why Investors Should Hold McKesson (MCK) Stock Now

McKesson (MCK) gains traction from a solid foothold in the pharmaceutical and medical supplies distribution market. However, the company is grappled with regulatory constraints in Canada.

Omnicell (OMCL) Rides on Innovation Despite Cost Concerns

Omnicell (OMCL) steadily sees a solid uptake of Omnicell XT. It also strikes various deals for the XR2 and IVX Workflow products.

Here's Why Investors Should Hold DENTSPLY (XRAY) Stock Now

DENTSPLY (XRAY) gains from strength in CAD/CAM dental imaging platform. However, sluggishness in the European business is worrisome.

LMNX or PACB: Which is a Better MedTech Investment Pick?

Luminex (LMNX) scores higher than Pacific Biosciences (PACB) considering growth projections and fundamentals.

LabCorp, GENFIT Tie-Up to Develop Test for NASH, Widen Suite

LabCorp (LH) continues to strengthen foothold in the diagnostics space through organic and inorganic means.

Here's Why You Should Add CVS Health to Your Portfolio Now

CVS Health (CVS) is optimistic about synergies from Aetna deal which will help create a robust platform to serve individuals better.

Solid Global Business Aids NuVasive Amid Pricing Pressure

Per NuVasive (NUVA), the international region holds significant growth opportunity. However, pricing pressure is a major headwind.

Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

Focus on emerging markets, improving margins and encouraging guidance provide PerkinElmer (PKI) a competitive edge in the MedTech space.

Here's Why Investors Should Bet on DexCom (DXCM) Right Now

A solid guidance for 2018 and lucrative deals make DexCom (DXCM) a promising investment pick.

Cardiovascular Systems Gets Approvals in Japan, Widens Suite

Cardiovascular Systems (CSII) continues to expand product portfolio to enhance market reach and versatility.

Here's Why You Should Invest in Wright Medical (WMGI) Now

A bullish outlook and a wide array of products make Wright Medical (WMGI) a promising investment pick.

Here's Why You Should Add Amedisys (AMED) to Your Portfolio

Amedisys (AMED) is developing and acquiring new business lines that will complement its existing home care and hospice business.

Walgreens Counts on International Progress, Strategic Deals

We are upbeat about Walgreens' (WBA) recent pact with Alphabet???s life sciences and healthcare segment, Verily, to coordinate on multiple projects with respect to chronic ailments.

Cardiovascular Systems Treats First Patient With Teleport

Cardiovascular Systems (CSII) expands product portfolio to enhance market reach and versatility.

Here's Why You Should Invest in Hill-Rom (HRC) Stock Now

Hill-Rom's (HRC) M&A pipeline continues to be strong.

Boston Scientific (BSX) to Buy Residual Shares of Millipede

Boston Scientific's (BSX) buyout of the leftover stake in Millipede will integrate the latter's IRIS Transcatheter Annuloplasty Ring System in the Structural Heart portfolio of the former.

Zimmer Biomet (ZBH) Thrives on New Projects, APAC Growth

Zimmer Biomet (ZBH) is performing well on the back of its two largest commercial projects, namely the Persona Revision system and the Rosa robotics knee application.

Ecolab Inks Deal With Clearway for Renewable Power Project

Ecolab's (ECL) virtual power purchase agreement with Clearway is part of a broader trend among corporate buyers. This will cover the company???s annual domestic energy use completely.